The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2017 May 3

PMID 28462454

Citations 54

Authors

John H Kehne

Brian D Klein

Shamsi Raeissi

Shalini Sharma

Affiliations

Soon will be listed here.

Abstract

For over 40 years, the National Institute of Neurological Disorders and Stroke/National Institutes of Health-funded Anticonvulsant Screening Program has provided a preclinical screening service for participants world-wide that helped identify/characterize new antiseizure compounds, a number of which advanced to the market for the treatment of epilepsy. The newly-renamed Epilepsy Therapy Screening Program (ETSP) has a refocused mission to identify novel agents which will help address the considerable remaining unmet medical needs in epilepsy. These include identifying antiseizure agents for treatment-resistant epilepsy, as well as anti-epileptogenic agents that will prevent the development of epilepsy or disease-modifying agents that will ameliorate or even cure established epilepsy and its comorbidities. This manuscript provides an overview of the ETSP's efforts aimed at identifying the next generation of therapeutic agents to further reduce the suffering from and burden of epilepsy.

Citing Articles

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept.

Kaminski K, Socala K, Abram M, Jakubiec M, Reeb K, Temmermand R Ann Neurol. 2024; 97(2):344-357.

PMID: 39512205 PMC: 11740271. DOI: 10.1002/ana.27124.

On-Demand Seizures Facilitate Rapid Screening of Therapeutics for Epilepsy.

Chen Y, Litt B, Vitale F, Takano H bioRxiv. 2024; .

PMID: 39464023 PMC: 11507747. DOI: 10.1101/2024.08.26.609726.

Dose-Dependent Induction of Differential Seizure Phenotypes by Pilocarpine in Rats: Considerations for Translational Potential.

Vasovic D, Stanojlovic O, Hrncic D, Sutulovic N, Veskovic M, Ristic A Medicina (Kaunas). 2024; 60(10).

PMID: 39459366 PMC: 11509679. DOI: 10.3390/medicina60101579.

Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates.

Jakubiec M, Abram M, Zagaja M, Socala K, Panic V, Latacz G ACS Chem Neurosci. 2024; 15(17):3228-3256.

PMID: 39166702 PMC: 11378297. DOI: 10.1021/acschemneuro.4c00438.

Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis.

Barker-Haliski M, Hawkins N Expert Opin Drug Discov. 2024; 19(9):1099-1113.

PMID: 39075876 PMC: 11390315. DOI: 10.1080/17460441.2024.2384455.

References

Smith M, Saunders G, Clausen R, Frolund B, Krogsgaard-Larsen P, Larsson O . Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC). Epilepsy Res. 2008; 79(1):6-13. PMC: 4314296. DOI: 10.1016/j.eplepsyres.2007.12.009. View

Allen A, Cossette P, Delanty N, Eichler E, Goldstein D, Han Y . De novo mutations in epileptic encephalopathies. Nature. 2013; 501(7466):217-21. PMC: 3773011. DOI: 10.1038/nature12439. View

Loscher W . Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016; 126:157-84. DOI: 10.1016/j.eplepsyres.2016.05.016. View

Stewart K, Wilcox K, Fujinami R, White H . Theiler's virus infection chronically alters seizure susceptibility. Epilepsia. 2009; 51(8):1418-28. DOI: 10.1111/j.1528-1167.2009.02405.x. View

White H, Alex A, Pollock A, Hen N, Shekh-Ahmad T, Wilcox K . A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia. 2011; 53(1):134-46. PMC: 3253224. DOI: 10.1111/j.1528-1167.2011.03338.x. View

Loscher W . The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?. Neurochem Res. 2016; 42(7):1926-1938. DOI: 10.1007/s11064-016-2025-7. View

Putnam T, Merritt H . EXPERIMENTAL DETERMINATION OF THE ANTICONVULSANT PROPERTIES OF SOME PHENYL DERIVATIVES. Science. 1937; 85(2213):525-6. DOI: 10.1126/science.85.2213.525. View

Srivastava A, White H . Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats. Epilepsy Res. 2012; 104(1-2):26-34. PMC: 3594324. DOI: 10.1016/j.eplepsyres.2012.10.003. View

Barker-Haliski M, Heck T, Dahle E, Vanegas F, Pruess T, Wilcox K . Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy. Epilepsia. 2016; 57(12):1958-1967. PMC: 5154893. DOI: 10.1111/epi.13577. View

10.

Grabenstatter H, Ferraro D, Williams P, Chapman P, Dudek F . Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia. 2005; 46(1):8-14. DOI: 10.1111/j.0013-9580.2005.13404.x. View

11.

Stewart K, Wilcox K, Fujinami R, White H . Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J Neuropathol Exp Neurol. 2010; 69(12):1210-9. PMC: 3077028. DOI: 10.1097/NEN.0b013e3181ffc420. View

12.

Grabenstatter H, Clark S, Dudek F . Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. Epilepsia. 2007; 48(12):2287-95. DOI: 10.1111/j.1528-1167.2007.01263.x. View

13.

Loewen J, Barker-Haliski M, Dahle E, White H, Wilcox K . Neuronal Injury, Gliosis, and Glial Proliferation in Two Models of Temporal Lobe Epilepsy. J Neuropathol Exp Neurol. 2016; 75(4):366-78. PMC: 5009480. DOI: 10.1093/jnen/nlw008. View

14.

Milligan C, Li M, Gazina E, Heron S, Nair U, Trager C . KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol. 2014; 75(4):581-90. PMC: 4158617. DOI: 10.1002/ana.24128. View

15.

Rowley N, White H . Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy Res. 2010; 92(2-3):163-9. DOI: 10.1016/j.eplepsyres.2010.09.002. View

16.

Srivastava A, Alex A, Wilcox K, White H . Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy. Epilepsia. 2013; 54(7):1186-94. PMC: 3735163. DOI: 10.1111/epi.12234. View

17.

Libbey J, Kirkman N, Smith M, Tanaka T, Wilcox K, White H . Seizures following picornavirus infection. Epilepsia. 2008; 49(6):1066-74. DOI: 10.1111/j.1528-1167.2008.01535.x. View

18.

Duveau V, Pouyatos B, Bressand K, Bouyssieres C, Chabrol T, Roche Y . Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy. CNS Neurosci Ther. 2016; 22(6):497-506. PMC: 6492802. DOI: 10.1111/cns.12523. View

19.

Smith M, Adams A, Saunders G, White H, Wilcox K . Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro. Epilepsy Res. 2007; 74(2-3):97-106. DOI: 10.1016/j.eplepsyres.2007.02.001. View

20.

Berg A, Berkovic S, Brodie M, Buchhalter J, Cross J, van Emde Boas W . Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010; 51(4):676-85. DOI: 10.1111/j.1528-1167.2010.02522.x. View